Trial of Safety Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

  • End date
    Dec 5, 2022
  • participants needed
  • sponsor
    GENUV Inc.
Updated on 5 August 2021
primary lateral sclerosis


The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.


Trametinib (SNR1611) is a MEK inhibitor that downregulates the MAPK/ERK pathway. In this study, the potential of MAPK/ERK pathway downregulation through trametinib (SNR1611) as a therapeutic treatment for amyotrophic lateral sclerosis (ALS) will be evaluated.

Condition Myelopathy, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Disorders, lou gehrig's disease
Treatment Trametinib (0.5 mg), Trametinib (1 mg), Trametinib (2 mg), Riluzole (100 mg)
Clinical Study IdentifierNCT04326283
SponsorGENUV Inc.
Last Modified on5 August 2021


Yes No Not Sure

Inclusion Criteria

Patients diagnosed as definite, probable or probable-laboratory-supported ALS according to El Escorial Criteria
Patients of less than 2 years after the onset of ALS
Patients who meet the criteria of K-ALSFRS-R score and forced vital capacity

Exclusion Criteria

Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor neuron disease
Patients who have history of ALS treatment of edaravone or stem cell therapy within 16 weeks before screening
Patients who have permanently ceased the administration of riluzole due to lack of tolerability and/or efficacy
Patients in Class II to IV according to the New York Heart Association functional classification. Patients with myocardial infarction, unstable arrhythmia, and/or significant cardiovascular disease such as unstable angina within 12 weeks before screening
Patients who do not meet the criteria of laboratory tests and medical/operation history
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note